Brief: Senti Bio Determines Recommended Phase 2 Dose (RP2D) In Phase 1 Study Of Senti-202

Senti Biosciences Holdings

05/08/2025 14:31

Aug 5 (Reuters) - Senti Biosciences Inc SNTI.O:

SENTI BIO DETERMINES RECOMMENDED PHASE 2 DOSE (RP2D) IN PHASE 1 STUDY OF SENTI-202 FOR THE TREATMENT OF RELAPSED/REFRACTORY HEMATOLOGIC MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA

SENTI BIOSCIENCES INC - SENTI-202 WELL-TOLERATED, NO DOSE LIMITING TOXICITIES

SENTI BIOSCIENCES - EXPECTS TO REPORT CLINICAL DATA, INCLUDING EFFICACY & DURABILITY, FROM EXPANSION COHORT BEFORE YEAR-END

Source text: ID:nGNX5LcXv7

Further company coverage: SNTI.O

 ((Reuters.Briefs@thomsonreuters.com;))